抗精神病药未治精神病患者多巴胺、GABA与谷氨酸能递质相互关系及与初始治疗反应关联
研究纳入29例抗精神病药未治首发精神病患者和31名健康对照,用PET测伏隔核多巴胺合成、MRS测前扣带回GABA和谷氨酸及丘脑谷氨酸,发现患者伏隔核多巴胺合成与前扣带回GABA关系异常且异常程度预测治疗反应,抗精神病药治疗改变多巴胺与丘脑谷氨酸关系。
要点
- 患者伏隔核多巴胺合成与前扣带回GABA呈正相关,健康对照呈负相关。
- 该异常关系由组别与GABA交互驱动,并与治疗反应相关。
- 两组伏隔核多巴胺合成与丘脑谷氨酸均正相关,患者治疗后关联减弱。
核心结论
- 抗精神病药未治首发精神病患者伏隔核多巴胺合成与前扣带回GABA水平关系异常,异常程度预测治疗效应。
- 抗精神病药治疗改变伏隔核多巴胺活性与丘脑谷氨酸水平的关系。
- 开发精神分裂症新疗法时应考虑多递质系统联合异常而非单一递质异常。
研究设计与样本
- 采用动态[18F]-DOPA PET动脉采血测伏隔核多巴胺合成k3,MRS测前扣带回GABA和谷氨酸及丘脑谷氨酸。
- 患者亚组在阿立哌唑单药治疗六周后复查:PET亚组10例患者,MRS亚组27例患者和30名健康对照。
- 使用多元线性回归和线性混合模型分析数据。
主要发现
- 健康对照中k3与GABA呈负相关(β=-0.15,p=0.03),患者中呈正相关(β=0.15,p=0.04)。
- k3与GABA异常关系由组别-GABA交互驱动(p=0.002),并与治疗反应相关(p=0.02)。
- k3与谷氨酸关系无显著组别交互,但两组丘脑k3与谷氨酸均呈正相关(p=0.04)。
- 患者治疗后丘脑k3与谷氨酸关联减弱(p=0.01)。
临床怎么用
- 伏隔核多巴胺合成与前扣带回GABA关系异常程度或可用于预测抗精神病药初始治疗反应。
- 开发精神分裂症新疗法时应考虑多递质系统联合异常而非单一递质异常。
局限性
- 患者复查亚组样本量较小(PET亚组10例,MRS亚组27例)。
- 原文未报告随访时长以外更长期的治疗反应数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preclinical evidence points to disturbances in neural networks in psychosis involving interrelations between dopaminergic-, GABAergic- and glutamatergic neurotransmitter systems. In support, we have previously shown that aberrant interrelations between these neurotransmitters, in contrast to individual transmitter systems, can separate antipsychotic-naïve first-episode psychotic patients (AN-FEP) from healthy controls (HC). Here, we characterized neurotransmitter interrelations, examined their association with treatment response, and explored the effect of treatment on the interrelations. Sixty participants (29 AN-FEP and 31 HC) underwent dynamic [18F]-DOPA PET with arterial blood sampling to measure dopamine synthesis (DS) (k3) in nucleus accumbens (NAcc) and magnetic resonance spectroscopy (MRS) to estimate levels of glutamate (Glu) in anterior cingulate cortex (ACC) and thalamus, and gamma-aminobutyric-acid (GABA) in ACC. A subgroup of the patients was re-scanned after six weeks antipsychotic monotherapy with aripiprazole (PET: 10 AN-FEP; MRS: 27 AN-FEP; 30 HC). Psychopathology was assessed at both visits. Multiple linear regression models and linear mixed models were used to analyze data. We found a negative association between k3 (dependent variable) and GABA in HC (β = -0.15, p = 0.03) and a positive association in patients (β = 0.15, p = 0.04). The aberrant relationship between k3 and GABA was driven by the group-GABA interaction (p = 0.002) and related to treatment response (p = 0.02). No significant group interactions were found for the interrelations between k3 and Glu, but a positive association was found between k3 and Glu in thalamus (p = 0.04) in both groups and the association decreased after treatment in AN-FEP (p = 0.01). The data show that DS in NAcc and GABA levels in ACC are inversely interrelated in AN-FEP, and that the degree of abnormality predicts treatment effect. Moreover, antipsychotic treatment alters the relationship between dopaminergic activity in NAcc and Glu levels in thalamus. The findings suggest that combined instead of single neurotransmitter disturbances should be considered when novel therapeutics are developed for schizophrenia. Clinical trial registration: The Pan European Collaboration on Antipsychotic Naïve Schizophrenia II (PECANSII) study, ClinicalTrials.gov Identifier: NCT02339844. https://www.clinicaltrials.gov/study/NCT02339844 .
引用
- Bojesen KB, Ambrosen KS, Sigvard AK, et al. Interrelations between dopaminergic-, gabaergic- and glutamatergic neurotransmitters in antipsychotic-naïve psychosis patients and the association to initial treatment response. Mol Psychiatry. 2025. PMID: 40940558. doi:10.1038/s41380-025-03229-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。